dBET6 is primarily used in biomedical research as a potent and selective degrader of BET (bromodomain and extra-terminal) proteins. It functions by recruiting BET proteins to the E3 ubiquitin ligase complex, leading to their ubiquitination and subsequent degradation by the proteasome. This mechanism makes dBET6 a valuable tool in studying the role of BET proteins in gene expression, cell proliferation, and inflammation. It has shown significant activity in cancer research, particularly in hematological malignancies such as leukemia and multiple myeloma, where BET proteins regulate oncogenes like MYC. By degrading these proteins, dBET6 can suppress tumor growth and induce apoptosis in cancer cells. Researchers also use dBET6 to explore epigenetic regulation and to develop targeted protein degradation therapies as an alternative to traditional inhibition-based drugs. Its use remains confined to preclinical studies and is not used in clinical or industrial applications outside of research.